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1. Introduction 
Endometriosis is characterised by the benign growth of endometrial glands and stroma on 
the surface of peritoneal tissues and other organs. It is generally regarded as an aberrant 
estrogen-dependent growth condition, which presents with symptoms of chronic pelvic 
pain, bleeding and infertility. Steroidal progestogens are already widely used in the 
treatment of the condition, dienogest (Visanne) the most recent of which has gained EU 
approval for clinical use (McCormack, 2010). Progestogens appear to work by both directly 
inhibiting the functional effects of estrogen on endometrial cell proliferation, and also 
suppressing ovarian function, to induce anovulatory amenorrhoea. The efficacy of this class 
of agents in patients with endometriosis, however, is relatively modest and the tolerability 
(breakthrough bleeding and bloating) as well as concerns on the long term safety (risk of 
breast cancer and thromboembolism, effect on bone mineral density) has also limited their 
broader utility. Progesterone receptor antagonists (PRAs) have emerged in recent years as 
an alternative approach to treating the disease. This class of agents has contrasting effects on 
reproductive function compared with progestogens. This review will focus on what we 
know about the PRA mechanism of action from pre-clinical in vitro and in vivo evidence 
and how clinical data have shaped confidence in this class of agents as a new approach to 
treating endometriosis symptoms and disease progression1. 
2. Progesterone receptor structure & function 
The steroid hormone, progesterone, is a key modulator of normal reproductive function, 
including ovulation, uterine and mammary gland development and the neurobehavioral 
expression associated with sexual responsiveness (Clarke & Sutherland, 1990; Lydon et al., 
1995). Progesterone is absolutely essential for the maintenance of pregnancy, maintaining 
uterine quiescence by suppressing expression of genes that mediate increased myometrial 
                                                 
1 Zhu Y, Bond J & Thomas P (2003) Identification, classification, and partial characterization of genes in 
humans and other vertebrates homologous to a fish membrane progestin receptor. Proc. Natl Acad. Sci. 
USA 100(5):2237-2242. 
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contractility, such as the oxytocin receptor. The physiological effects of progesterone (P4) are 
principally mediated by interaction with two specific intracellular receptors termed PR-A 
and PR-B. PR-A and PR-B are members of the nuclear receptor superfamily of transcription 
factors (Mangelsdorf et al., 1995; McKenna et al., 2009; O’Malley & Conneely, 1992; Tsai & 
O’Malley, 1994). Nuclear hormone receptors regulate gene transcription by discriminative 
binding to specific DNA sequences, so-called progesterone response elements (PREs) 
Specific interactions with co-activator and/or co-repressor proteins, induced by ligand 
binding, trigger interactions with the RNA polymerase complex (McKenna & O'Malley, 
2001). PR-A and PR-B are expressed from a single gene as a result of transcription from two 
alternative promoters and translation initiation at two alternative initiation codons (Kraus et 
al., 1993). The human PR-A and PR-B are identical except for an additional N-terminal 164 
amino acid sequence present in PR-B. Both isoforms have two activation function domains, 
AF-1 proximal to the DNA-binding domain, and a ligand-dependent AF-2 domain in the C 
terminus (Tetel et al., 1999). By virtue of the longer N-terminus, PR-B also has a unique AF-3 
domain that may contribute to its differential trans-activation properties compared with PR-
A (Tung et al., 2006).  
Ligand binding (progesterone as well as other synthetic PR ligands such as progestogens 
(e.g. dienogest, tanaproget, medroxyprogesterone acetate), the progesterone receptor 
antagonists (PRAs, such as RU-486) and modulators (e.g. J-867)) triggers a conformational 
change that causes the dissociation of bound heat shock proteins, receptor 
phosphorylation, receptor dimerisation, nuclear translocation and DNA binding. Binding 
occurs at specific PRE sequences in promoters of progesterone response genes, and alters 
transcriptional activity, negatively or positively, depending on PRE sequence, the 
conformation of the ligand-bound complex and cell-specific context. In the presence of 
steroidal PRAs, such as RU-486, the complex becomes transcriptionally inactive due to 
recruitment of co-repressors such as NCoR1 (Wagner et al., 1998), whereas selective PR 
modulators, such as J-867, elicit a mixed agonist/antagonist response (Elger et al., 2000; 
Madauss et al., 2007). 
Studies in mice with selective ablation of PR isoforms have revealed that PR-A is necessary 
for ovulation and modulates the anti-proliferative effects of progesterone in the uterus. In 
contrast PR-B knockout mice are fertile and sustain a normal pregnancy, but PR-B appears 
to be required for normal mammary gland development and function (Mulac-Jericevic & 
Conneely, 2005). In an attempt to understand the function of PR-B in the endometrium, one 
group has used PRAs and siRNA to knockdown gene expression in an immortalised human 
endometrial stromal cell line (Wu & Guo, 2006; Wu et al., 2008). Ablation of PR-B promoted 
cellular proliferation, by approximately 20% compared with control, supporting the notion 
that PR-B acts as a break on progesterone function. It is noteworthy that breast and 
endometrial malignancy is often accompanied by disruption of PR-A and PR-B expression 
or altered functional PR responses (Arnett-Mansfield et al., 2004; De Vivo et al., 2002; 
Kobayashi et al., 2010; McGowan et al., 2004), an observation which has triggered interest in 
the potential utility of PRAs for oncology (Fuhrmann et al., 2000; Poole et al., 2006; Tieszen 
et al., 2011; Wiehle et al., 2011). Recent evidence has also confirmed the existence of a 
functional third isoform, PR-C which lacks AF-2 and AF-3 domains and appears to act as a 
sink for progesterone and have a function in regulating the onset of parturition (Condon et 
al., 2006).  
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Beyond the genomic function of progesterone mediated by PR-A and PR-B, progesterone 
also appears to elicit non-genomic activity. Neurosteroidal function of progesterone and 
progesterone metabolites, such as allopregnelone (3α-hydroxy-5α-pregnan-20-one), 
augment GABAergic channel burst durations by increasing the opening frequency through 
positive allosteric modulation in the hypothalamus (Henderson, 2007). In the female rat, 
direct administration of allopregnelone in specific regions in the hypothalamus rapidly 
facilitates lordosis, suggesting a direct non-genomic effect on reproductive function. Outside 
of the predicted protection from catamenial exacerbation of epileptic seizures and 
premenstrual dysphoric disorder by neurosteroids (Biagini et al., 2010), the non-genomic 
effects of progesterone in reproductive function in the female human have been less well 
characterised. Several other reported progesterone receptors (mPR, PGRMC1 and CatSper, 
for instance) have also been touted to contribute to the non-genomic effects of progesterone 
(Dressing et al., 2011; Gellersen et al., 2009; Lishko et al., 2011; Zhu et al., 2003). Based on 
expression data and some functional characterisation both mPR and PGRMC1 may have a 
role in reproductive function and are speculated to regulate implantation and myometrial 
contractility. Whilst there are no evidence reported suggesting a contributing role for mPR 
or PGRMC1 in endometriosis, this is not the case for PR. 
3. Evidence of progesterone resistance in women with endometriosis 
The uterus is composed of heterogeneous cell types which undergo synchronous waves of 
proliferation and differentiation in response to cyclical changes in estrogen (E2) and 
progesterone levels. The spatiotemporal expression of PRs in epithelial, stromal and 
myometrial cellular compartments are under the control of estrogen, the primary 
endometrial mitogen. Progesterone appears to exert proliferative function or induce 
differentiation depending on the cell type; on epithelia, progesterone, acting via stromal 
PRs, inhibits estrogen-driven cell proliferation and on stroma progesterone appears to 
orchestrate a more complex pattern of proliferation and differentiation.  
While the actions of progesterone are critical to the establishment and maintenance of 
pregnancy, approximately one third of women with endometriosis also present with 
infertility. For some women, the loss of tubal patency, the modification of the pelvis and the 
inflammation associated with condition appear to be causally related to the presentation of 
infertility. However, the characterization of the eutopic endometrium from women with 
endometriosis has also revealed many defects, including altered patterns of angiogenesis, 
dyssynchrony with the window of implantation as well as ultra structural abnormalities 
which may contribute to the infertility. Supporting this, isolated endometrial stromal 
fibroblasts from women with endometriosis do not appear to undergo a normal 
decidualisation response (Aghajanova et al., 2010), suggesting an impairment of the 
progesterone-mediated differentiation programme. Specific alterations in the expression 
molecular markers of endometrial receptivity have also been widely documented, especially 
the integrin αvβ3, certain steroid hormone receptors and HOXA10 gene expression, the latter 
of which has been identified from a genome wide association study of moderate to severe 
endometriosis as a potential candidate disease locus with proximity to the 7p15.2 SNP 
association (Painter et al., 2011).  
Early studies also pointed to alteration in the normal pathways of estrogen metabolism in 
ectopic endometrial tissue; specifically expression of 17βHSD-2, the enzyme responsible for 
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the conversion of estradiol to estrone appears to be reduced compared with the eutopic 
compartment (Bulun et al., 2010; Zeitoun et al., 1998). As 17βHSD-2 is a progesterone 
response gene, one group has published evidence to suggest that this may be due to 
apparent reduction in PR levels and especially in PR-B in ectopic tissue (Attia et al., 2000; 
Wu et al., 2006). However, this signpost to progesterone resistance has had relatively little 
formal observational replication; indeed others have not been able to find evidence of 
alteration in the PR-A/PR-B ratio (Bergqvist & Ferno, 1993; Igarashi et al., 2005). 
Furthermore, decrease in PR-A mRNA and an increase in the PR-B to PR-A ratio and total 
PR protein levels have been detected in eutopic samples obtained from a murine 
endometriosis model (Lee et al., 2009). PR expression has also been found to be similarly 
unaltered in the eutopic endometrium of baboons with experimentally induced 
endometriosis compared with baseline (Fazleabas et al., 2003). 
Microarray studies performed on isolated cells, eutopic/ectopic tissue biopsies and cells 
excised by laser capture microdissection from patients have been revealed several pathways 
of altered gene expression. For instance Kao et al (2002; 2003) collected biopsies from eutopic 
endometrium from normal women and women with endometriosis at days 8-10 after the 
mid-cycle LH surge and performed a microarray analysis to identify differentially expressed 
genes. Whilst a formal analysis of progesterone-response genes, whose expression was 
either elevated or suppressed in diseased versus normal tissue, was not undertaken, the 
expression of several progesterone response genes, including Dickkopf-1 and glycodelin, 
was suppressed in diseased tissues samples. The suppression of the Dickkopf-1 response 
has been supported by more recent studies of progesterone response in isolated human 
endometrial stromal fibroblasts from normal women and women with endometriosis 
(Aghajanova et al., 2011). In studies comparing ectopic and eutopic gene expression 
obtained from women with endometriosis one of the key observational fingerprints was an 
impairment in the normal progesterone response, especially the expression of PR, IHH, 
FOXO1A and Cyp26A1 amongst others (Burney et al., 2007). Relatively few genes have been 
qualified as progesterone responsive by testing with a PRA and this has limited larger data 
assignments in published microarray data. Even when microarray analysis was performed 
on RNA extracted from human endometrial explants cultured in the presence of E2/P4 and 
treated with RU-486, only a small population of gene expression were differentially 
regulated (Catalano et al., 2003). Of these, JAK1 and JNK1 appeared to be down regulated in 
the presence of RU-486. These observations are intriguing as JNK activity is unregulated in 
women with endometriosis (Uz et al., 2011) and in a Scid mouse experimental model of 
endometriosis, JNK inhibitor treatment reduces disease burden (Altan et al., 2008).  
Taken together, while the data support the notion that there is an abnormal progesterone 
response in eutopic and ectopic endometrial compartments in women with endometriosis, it 
is not clear whether this is a direct effect, causally associated with infertility, or could be 
used for diagnostic purposes. One of the key gaps is that many of these genes have not been 
formally tested to be directly PR mediated, and therefore lack the qualification of alteration. 
Another, somewhat controversial, observation linked with the molecular basis of 
progesterone resistance has been revealed from studying functional polymorphisms in the 
promotor region of PR. A putative functional polymorphism in the PR promoter (+331C/T; 
rs10895068), creates an additional TATA box that provides a unique transcriptional start site 
and favours increased production of PR-B relative to PR-A (De Vivo et al., 2002). Berchuck et 
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al. (2004) first suggested a reduced risk of endometriosis associated with the T allele of the 
+331 variant and because of increased production of PR-B, this variant was suggested to 
reduce the risk of endometriosis. However the original findings suggesting that PR-B is not 
expressed in ectopic lesions have not had broad replication and Treloar et al. (2005) found 
no association with endometriosis and this variant either in a large study which included 
more than 900 families. Another putative functional variant in the PGR gene is termed the 
PROGINS allele. Cells prepared from the eutopic endometria of women carrying the 
PROGINS allele appear to respond with greater proliferative capacity to estradiol and 
progesterone, supporting the contention that the PROGINS polymorphism enhances the 
endometriosis phenotype (D'Amora et al., 2009). However while several studies have 
suggested that the variant increases susceptibility to endometriosis (De Carvalho et al., 2007; 
Lattuada et al., 2004; Wieser et al., 2002), others have not found an association (Govindan et 
al., 2007; Treloar et al., 2005; van Kaam et al., 2007). Therefore taken together, there is only 
modest supporting evidence of altered progesterone receptor expression, and progesterone 
resistance in contributing to endometriosis susceptibility and disease symptoms. 
Notwithstanding this, the current clinical utility of progesterone receptor agonists and 
anticipated benefit of PRAs, outweighs the confidence in PR as a therapeutic target attained 
from a molecular understanding of the protein and condition. 
4. Discovery of small molecule modulators of PR function 
The identification of drug-like, potent and selective PR antagonists has been challenging. As 
well as being highly lipophilic, the ligand binding sites between homologous NHRs are 
highly conserved and PR has the highest sequence homology with GR, AR, MR and ER 
(Figure 1). Early classes of anti-progestagens were poorly selective, yet some, such as 
gestrinone, still found clinical utility in the treatment of endometriosis (Cornillie et al., 1986; 
Coutinho, 1982). Furthermore, the ligand binding domains of PR-A and PR-B are identical 
and yet several in vitro and in vivo lines of evidence suggest that the effects of progesterone 
on transcriptional activation and repression by PR-A and PR-B are different (Conneely et al., 
2001; Tung et al., 2006). To date, however, there are no agonist or antagonist agents that 
have been characterised with selectivity for PR-A over PR-B or vice versa.  
The development of selective and safe steroidal PRAs has been challenging, both due to 
reported hepatoxicity as well as potential dose-limiting anti-glucocorticoid effects, due to 
lack of selectivity (Robertson et al., 1999). More recently, an additional concern has emerged 
following histological evaluations of subjects dosed for more than 3 months on steroidal 
PRAs. The endometrium of these individuals undergoes a characteristic cystic histological 
change which may be difficult to distinguish from endometrial hyperplasia without 
specialist evaluation (Ioffe et al., 2009; Mutter et al., 2008; Williams et al., 2007).  
Mifepristone/RU-486, the founding member of the steroidal class of PRAs, was originally 
produced by Roussel-Uclaf and licensed for use for medical abortion and as an emergency 
contraceptive. The in vivo pharmacokinetic/pharmacodynamic profile of RU-486 is 
challenging to model as RU-486 generates a large number of pharmacologically active 
metabolites (Heikinheimo et al., 1987). Since its identification, >100 related analogues, 
principally by modifying the C-11 and/or C-17 positions of the steroid ring, have been 
synthesized and have shown all degrees of anti-progestagenic activity. The pharmacological 
profile of these examples range from pure antagonists, such as RU-486 to those with mixed 
antagonist/agonist activity, such as J-867 (Table 1).  
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Fig. 1. (a) X-ray structure of progesterone (cyan) bound to the PR ligand binding pocket 
(pink) (Williams & Sigler, 1998) and overlaid with the x-ray co-ordinates of GR, MR and AR 
(in green) to illustrate the high degree of structural similarity between homologous NHRs 
(b) Phylogentic tree illustrating the sequence similarity of homologous NHRs with PR. 
More recently, several alternative non-steroidal chemical PRA scaffolds have been 
published. These might have advantages over the steroidal templates due to simpler 
synthetic route, and potential for greater selectivity and metabolic stability compared with 
steroidal templates (Dack et al., 2010; Fensome et al., 2008; Terefenko et al., 2005; Zhang et 
al., 2002),. With a few exceptions, these classes of agents tend to mimic the steroid A ring 
ketone with a cyanoaryl group isostere, as is also seen with tanaproget, the non-steroidal 
progestogen (Fensome et al., 2005). 
Steroidal PRAs have been characterised as facilitating PR dimerisation and nuclear 
translocation, but induce a conformation of the DNA-bound complex which recruits co-
repressors to directly shutdown transcriptional PRE activity and other transcriptional 
promoters by trans-repression. The pharmacological profile of the non-steroidal compounds 
appears to be subtly different from steroidal examples (Howe et al., 2011; Zhang et al., 2007). 
In vitro pharmacological profiling of PRA-910 and PF-02413873 has indicated that at low 
concentrations the compounds inhibit the expression of progesterone-reporter genes, but at 
high concentrations, they induce agonism. For PF-02413873, the inhibition of progesterone-
reporter gene expression appears to be due to blocking PR nuclear translocation and then at 
high concentrations PF-02413873 facilitates it, recruits co-activators and induces gene 
transcription.  
 
Compound Structure Pharmacology data In vivo observations Reference 
Non-steroidal PRAs
PF-02367982 
N
N
O
N
NH
O
 
PR binding Ki=76 nM; 
functional IC50=40.3 
nM 
>3000x functional 
selectivity over GR, 
AR, MR 
Dose dependent 
inhibition of 
arborisation of the 
immature rabbit and 
luteal phase 
endometrium of the 
intact macaque 
(de Giorgio-
Miller et al., 
2008) 
Table 1. Pharmacological properties of key non-steroidal and steroidal PRAs 1 In these 
assays, the activity of RU-486 was PR binding IC50=9 nM; T47D IC50=7.6 nM; GR binding 
IC50=10 nM; IC50=5.9 nM; AR binding IC50=45 nM; 2 In these assays, the activity of RU-486 
was PR binding IC50=0.028 nM; GR binding IC50=2.2 nM; AR binding IC50=10 nM 
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PF-02413873 
N
N
O
N
S
O
O
 
PR binding Ki=2.6 
nM; functional Ki=9.7 
nM; pKB= 8.0 
[Agonist format: 
~25% activation at 10 
μM] 
AR binding IC50=2100 
nM; functional 
Ki=1130 nM  
MR functional Ki=307 
nM  
GR binding Ki=410 
nM; functional 
Ki=2710 nM
Dose dependent 
inhibition in functionalis 
thickness & BrdU 
incorporation of 
follicular phase macaque 
endometrium; maximum 
effects at 10 mg/kg (p.o, 
b.i.d) 
(Howe et 
al., 2011) 
PRA-910 
F
N
H
O
O
CN
 
PR binding Kd=4.4 
nM; functional 14 nM  
[Agonist format: ~60-
70% activation at 0.1 
μM 
AR binding IC50=1292 
nM 
GR binding IC50=1756 
nM 
MR binding IC50=2369 
nM 
ER binding IC50 
>10000 nM
Dose dependent 
inhibition of the P4-
induced rat decidual 
response (mean ED50 
=0.3 mg/kg) with no 
evidence of agonism at 
10 mg/kg. 5 mg/kg 
reduced BrdU 
incorporation in the 
E2/OVX macaque, but 
no effect on endometrial 
thickness c.f. control 
(Zhang et 
al., 2002; 
2007) 
WAY-255348 
N
F
N
H
O
NC
 
PR binding IC50=5 
nM; functional IC50=5 
nM 
AR functional 
IC50=196 nM 
MR functional 
IC50=3700 nM 
>No significant 
activity at GR, ER
Inhibition of P4-induced 
rat decidual response 
(ED50 = 0.3 mg/kg). Dose 
dependent inhibition of 
ovulation in the 
macaque. All the 
animals treated at 10 
mg/kg had thin-
atrophied endometria 
(Fensome et 
al., 2008) 
Steroidal PRAs 
RU-486 / 
mifepristone 
N
O
H OH
H
H
 
PR binding Ki=0.5 
nM; T47D IC50=0.2 nM
AR functional C50=20 
nM 
GR binding Ki=1.4 
nM; Functional IC50=3 
nM  
MR functional IC50=3 
nM 
 
Dose dependent 
induction of menses in 
intact and E2/P4 
artificially cycled 
macaque. Inhibition of 
ovulation and 
endometrial 
proliferation. ~75% 
reduction in peritoneal 
disease volume in a 
surgical model of 
endometriosis in the 
macaque 
(de Giorgio-
Miller et al., 
2008; Grow 
et al., 1996; 
Slayden & 
Brenner, 
1994; 
Slayden et 
al., 2001; 
Wolf et al., 
1989) 
Table 1. (continuation) Pharmacological properties of key non-steroidal and steroidal PRAs1 
In these assays, the activity of RU-486 was PR binding IC50=9 nM; T47D IC50=7.6 nM; GR 
binding IC50=10 nM; IC50=5.9 nM; AR binding IC50=45 nM; 2 In these assays, the activity of 
RU-486 was PR binding IC50=0.028 nM; GR binding IC50=2.2 nM; AR binding IC50=10 nM  
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CDB-4124 / 
proellex 
N
O
H
H
H
O
O
OMeO
 
PR binding IC50=19 
nM; T47D functional 
IC50=11 nM1 
GR binding IC50=17 
nM IC50=130 nM  
AR binding IC50=288 
nM 
Dose dependent 
suppressed cell 
proliferation and 
tumour latency in a N-
methyl-N-nitrosourea-
induced mammary 
carcinogenesis rat model 
(Attardi et 
al., 2002; 
Brenner et 
al., 2010; 
Wiehle et 
al., 2011) 
CDB-2914 / 
ulipristal 
N
O
H
H
H
O
O
O
 
PR binding IC50=7 
nM; T47D functional 
IC50=7 nM 
GR binding IC50=18 
nM; functional 
IC50=73.8 nM  
AR binding IC50 = 65 
nM1 
Intrauterine delivery of 
CDB-2914 suppressed 
endometrial growth and 
menstruation in 
artificially cycled Rhesus 
macaques 
(Attardi et 
al., 2002; 
Brenner et 
al., 2010; 
Gainer & 
Ulmann, 
2003) 
ZK-230211 / 
linaprostone 
O
H
H
H
CF
2
CF
3
OH
O
 
PR binding IC50 = 
0.0036 nM 
GR binding IC50 = 16 
nM 
AR binding IC50 = 54 
nM2 
Dose dependent 
interruption of 
pregnancy in the rat and 
reduction in tumour 
mass in a DMBA-
induced rat mammary 
tumour model. Dose 
dependent inhibition of 
endometrial growth in 
the macaque 
(Afhüppe 
et al., 2010; 
Fuhrmann 
et al., 2000; 
Slayden et 
al., 2001) 
J-867 / 
asoprisnil 
O
H
H
H
OMe
N
OH OMe
 
PR functional IC50=0.2 
nM 
AR functional 
IC50=6.1 nM 
GR functional IC50=85 
nM  
MR functional 
IC50=1.6 µM 
ER functional IC50= 
1.9 µM  
Partial agonist 
properties in McPhail’s 
assay. Marginal labour-
inducing activity during 
mid-pregnancy and 
ineffective in inducing 
preterm parturition in 
the guinea pig. 
Abolition of menstrual 
cyclicity and induction 
of endometrial atrophy 
in the macaque 
(DeManno 
et al., 2003; 
Elger et al., 
2000; 
Fensome et 
al., 2008) 
ORG-31710 
O
O
H
H
H
N
 
PR relative binding 
affinity equivalent to 
RU-486. 
30 fold lower GR 
relative binding 
affinity c.f. RU-486 
ORG-31710 
administered with 
desogestrel reduced the 
incidence of 
unscheduled vaginal 
bleeding c.f. desogestrel 
alone in the macaque 
(Kloosterbo
er et al., 
1994; 2000; 
Verbost et 
al., 2005) 
 
Table 1. (continuation) Pharmacological properties of key non-steroidal and steroidal PRAs 1 
In these assays, the activity of RU-486 was PR binding IC50=9 nM; T47D IC50=7.6 nM; GR 
binding IC50=10 nM; IC50=5.9 nM; AR binding IC50=45 nM; 2 In these assays, the activity of 
RU-486 was PR binding IC50=0.028 nM; GR binding IC50=2.2 nM; AR binding IC50=10 nM 
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ZK-98299 / 
Onapristone 
O
H
H
H
OH
N
OH
 
PR relative binding 
affinity equivalent to 
RU-486 
 
Inhibition of 
arborisation of the 
immature rabbit. 
Reduction in cell 
proliferation of cells in 
ectopic lesion in a rat 
endometriosis model. 
Inhibition of ovulation 
and endometrial growth 
in monkeys
(Elger et al., 
2000; 
Gopalkrishn
an et al., 
2003; 
Ishwad et 
al., 1993; 
Stoeckeman
n et al., 
1995) 
ZK-137316  PR relative binding 
affinity equivalent to 
RU-486 
 
Inhibition of 
arborisation of the 
immature rabbit. 
Reduction in cell 
proliferation of cells in 
ectopic lesion in a rat 
endometriosis model. 
Inhibition of ovulation 
and endometrial growth 
in macaques. 
(Borman et 
al., 2003; 
Slayden et 
al., 1998; 
2001; 
Slayden & 
Brenner, 
2003; 
Stoeckeman
n et al., 
1995; 
Zelinski-
Wooten et 
al., 1998) 
Table 1. (continuation) Pharmacological properties of key non-steroidal and steroidal PRAs 1 
In these assays, the activity of RU-486 was PR binding IC50=9 nM; T47D IC50=7.6 nM; GR 
binding IC50=10 nM; IC50=5.9 nM; AR binding IC50=45 nM; 2 In these assays, the activity of 
RU-486 was PR binding IC50=0.028 nM; GR binding IC50=2.2 nM; AR binding IC50=10 nM 
5. Pre-clinical effects of PR antagonists in pre-clinical models 
The study of the effects of PRAs in pre-clinical models has shed light on the site of and 
mechanism of action of PRAs in normal reproductive physiology and disease. The classical 
models for quantifying PRA activity are the modified assay in juvenile rabbits according to 
McPhail (McPhail, 1933), the induction of luteolysis in the guinea pig (Elger et al., 2000) and 
the inhibition of decidualisation in the rat. For the purposes of this review, I have focussed 
on the pre-clinical models which have been used to support a role for PR in the pathogenesis 
and treatment of endometriosis, principally focussing on studies in the rodent and macaque. 
Many data have been acceded from studies in the normal animal, but several experimental 
models of endometriosis have been also developed in normal as well as immune 
compromised rodents and non-human primates (D'Hooghe et al., 2009; Grummer, 2006; 
Laschke & Menger, 2007). In these models, cystic ectopic endometrial lesions develop 
following the transplantation of syngeneic or human uterine endometrial tissue under the 
control of ovarian estradiol. Measuring temporal changes in the size of these lesions and 
their proliferative capacity as well other aspects of the disease presentation is a powerful 
pre-clinical yardstick for testing the efficacy of experimental drugs. 
5.1 Rodent 
Mouse knockout studies have elegantly described differences in the function of PR-A and 
PR-B. Both PR null mutation (PRKO) and selective disruption of the PR-A isoform (PRAKO) 
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in the mouse leads to a failure of ovulation due to disabled follicular rupture in response to 
gonadotrophin stimulation (Lydon et al., 1995; Mulac-Jericevic & Conneely, 2005). The 
histological characterisation of uteri from PRKO mice confirmed extensive epithelial 
hyperplasia (Lydon et al., 1995). In contrast, the stromal compartment was distinctly 
oedematous and infiltrated with neutrophils and macrophages. While these data strongly 
support the notion of PR in suppressing ER function in the uterus, the cystic dilation, 
epithelial hyperplasia and associated inflammation are also histological hallmarks of 
endometriosis, especially those characterised in rodent disease models (Bruner et al., 1997; 
Grummer, 2006; Hull et al., 2003; Vernon & Wilson, 1985). The endometrial epithelial 
hyperplasia observed in the uteri of PRAKO mice was similar to that observed for PRKO 
mice suggesting that PR-B is unable to compensate for the loss of PR-A (Mulac-Jericevic et 
al., 2000). In contrast, ovarian and uterine response to E2/P4 appear to be normal in PR-B 
knockout mice, whereas mammary lobuloalveolar development was markedly reduced due 
to decreased ductal and alveolar epithelial cell proliferation (Mulac-Jericevic et al., 2003). 
Taken together these findings demonstrate the extremely important role PR plays in 
regulating ovarian function and spatiotemporal cell growth in different tissue compartments 
in response to E2/P4 in the mouse. 
PRKO mice have been used to explore the role of PR in the development and growth of 
ectopic lesions in a syngenic mouse model of endometriosis (Fang et al., 2004). In this study, 
the volumes of PRKO lesions collected from animals treated with E2 were approximately 
20% larger than those from corresponding wild-type animals. Additionally, the effects of P4 
on PRKO lesions were ablated compared with those from wild-type animals, underscoring 
the important role that PR plays in regulating E2-dependent cell proliferation in the rodent.  
Whilst the evaluation of gene ablation on eutopic and ectopic endometrial cell growth has 
been revealing, the studies of pharmacological modulation contrast these observations to a 
certain extent as both progestogens and PRAs reduce ectopic endometrial cell proliferation 
and disease burden in pre-clinical rodent models of endometriosis (Bruner-Tran et al., 2006; 
Chwalisz et al., 1998; Katayama et al., 2010; Katsuki et al., 1998; Stoeckemann et al., 1995). 
An explanation of this phenomenon compared with the phenotype of PRKO animals has 
been revealed by studies with PRAs in the non-human primate. 
5.2 Macaque 
Given the evolutionary and physiological proximity of the macaque menstrual cycle with 
the human, many groups have evaluated the role of PR and the effects of PRAs on the 
macaque endometrium. Most data revealing the effect of PRAs on the endometrium have 
come from studies evaluating the effects of steroidal PRAs. When administered acutely after 
the mid-cycle LH surge, or during the progesterone phase in artificially cycled animals, 
PRAs impair the effects of progesterone on endometrial arborisation and induce an early 
menstruation. In the intact macaque, animals undergo an anovulatory amenorrhoea under 
the influence of continuous steroidal PRA exposure (Brenner et al., 2010; Slayden et al., 
2001). In these animals, the endometrium is characterised by decreased wet weight, 
thickness and mitotic activity. The endometrium undergoes a characteristic atrophy and 
compaction of the stroma, glandular apoptosis as well as degeneration of the endometrial 
spiral arterioles. These effects are characteristically anti-estrogenic in nature, and yet the 
effects occur in the presence of mid-follicular levels of E2, levels that should be sufficient to 
www.intechopen.com
Progesterone Resistance and Targeting  
the Progesterone Receptors: A Therapeutic Approach to Endometriosis 
 
167 
facilitate endometrial growth. Studies in ovariectomised (OVX) and E2-supplemented 
macaques, have been perhaps even more revealing with respect to the mechanism driving 
this effect, especially the direct as well as indirect effects of PRAs on the hypothalamic-
pituitary-gonadal axis and endometrium. Firstly, RU-486 has been shown to suppress the 
estrogen-induced LH surge in the OVX macaque (Wolf et al., 1989), underwriting a role for 
PR in regulating the hypothalamic-pituitary axis in higher species as suggested by early 
studies in knockout mice (Conneely et al., 2001). Furthermore, as RU-486 does not appear to 
blunt GnRH-induced LH secretion in the macaque (Heikinheimo et al., 1995), this has 
suggested that PRAs directly block ovarian folliculogenesis. In intact macaques with PRA 
doses that are too low to block ovulation or in the OVX/E2 macaque, steroidal PRAs that 
include can also directly suppress the effects of estrogen on the endometrium by inhibiting 
cell proliferation and thickness suggesting that PR regulates reproductive function at 
multiple points (Brenner et al., 2010; DeManno et al., 2003; Hodgen et al., 1994; Ishwad et al., 
1993; Slayden et al., 1998; 2001; 2006; Wolf et al., 1989; Zelinski-Wooten et al., 1998). 
While many studies have been commonly undertaken by oral or systemic administration of 
PRAs, principally RU-486, some studies have also been undertaken by local, intrauterine 
administration, such as those with CDB-2914 and ZK-230211(Brenner et al., 2010; Nayak et 
al., 2007). In each case, the intrauterine administration resulted in the characteristic 
inhibition of normal menstrual bleeding, atrophy of endometrial spiral arterioles and 
functionalis thickness, consistent with observations from systemic administration (Figure 2). 
Unfortunately neither of these studies were supported with a confirmation of drug 
exposure, comparing the local versus systemic exposure to demonstrate that the effects were 
mediated by a local site of action and not an indirect effect. Nonetheless the data support 
others which suggest that PRAs can work locally to block estrogen effects on endometrial 
growth in the macaque. 
a                                                        b
Blank-IUS                       CDB-2914-IUSBlank-IUS               CDB-2914-IUS
 
Fig. 2. (a) Induction of endometrial atrophy by CDB-2914-intrauterine system (IUS) versus 
blank-IUS (taken from (Brenner et al., 2010) with permission); E, endometrium; Myo, 
myometrium (original magnification ×25). (b) AR staining on endometrial tissue samples 
taken from macaques treated with CDB-2914-IUS or blank-IUS (original magnification ×340). 
The mechanism of attenuation of estradiol effects on the endometrium is not well 
understood, and although steroidal PRAs appear to block cell proliferation in various in 
vitro cell-based systems, the concentrations needed for this effect are considerably greater 
than those which elicit the effect in vivo (Freeburg et al., 2009a; Goyeneche et al., 2007; 
Murphy et al., 2000; Ohara et al., 2007; Wu & Guo, 2006). One clue to a potential mechanism 
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has emerged from observations of elevated endometrial androgen receptor (AR) expression 
(Narvekar et al., 2004; Slayden & Brenner, 2003) following PRA administration and the 
known effects of AR modulators (e.g. danazol) on endometrium (Rose et al., 1988).  
These observations have been functionally evaluated further (Slayden & Brenner, 2003) in 
which OVX/E2 macaques were continuously treated with ZK-137316 or together with the 
AR antagonist, flutamide, for 28 days. Flutamide reversed the inhibitory effects of ZK-
137316 on the E2/OVX endometrium, restoring levels of endometrial proliferation and 
thickness to control levels (Table 2). 
 E2 alone E2/ZK-137316  
(0.1 mg/kg i.m.) 
E2/ZK-137316 (0.1 mg/kg i.m.) + 
Flutamide (2 mg/kg s.c.) 
Weight (mg) 360 ± 32 64 ± 10b 265 ± 92 
Thickness (mm) 3.3 ± 0.4 1.1 ± 0.3b 2.2 ± 0.6 
Stromal 
compactionc 
45.5 ± 3.4 142.3 ± 63.7b 54.0 ± 4.6 
Mitotic indexd 6.3 ± 0.6 0.3 ±0.3b 5.2 ± 3.8 
Table 2. Morphometric assessment of androgen receptor blockade of ZK-137316 effects on 
OVX/E2 macaquesa (Adapted from (Slayden & Brenner, 2003)) aAll values represent mean ± 
SE; bp<0.05 compared with values in the same row; cstromal cells/10,000 µm2; dmitotic 
cells/1000 epithelial cells 
That flutamide did not appear to inhibit the PR activity of ZK-137316 (i.e. ZK-137316-
induced menstruation in E2/P4 artificially cycled animals in the presence of flutamide), 
suggested that the endometrial anti-proliferative effects of steroidal PRAs like ZK-137316 
are mediated by a mechanism involving AR. However, despite this extremely important 
observation, the seminal Slayden publication has not been followed up further. For instance, 
it is not clear what ligand is driving the AR effect, as testosterone levels do not appear to be 
altered in ZK-137316 treated animals, or how the signal is transduced through AR; if it is 
genomic or non-genomic. If AR is inducing a genomic effect, what are the transcripts that 
are altered and confer the inhibitory effect on PRA? Other important and, as yet, 
unaddressed questions also include whether these effects are only manifested only by the 
steroidal class of PRAs, but the observation that RU-486 can elevate endometrial AR 
expression in women goes some way to understanding the translational significance of the 
macaque findings (Narvekar et al., 2004).  
Non-steroidal classes of PRAs have also been studied in a similar way in the macaque. Of 
the novel class of cyanophenoxypyrazoles, PF-02367982 dose-dependently inhibited the 
progesterone-mediated aborisation of the endometrium and delayed menses induction 
when dosed for 20 days from the start of the menstrual cycle. PF-02367982 also increased AR 
protein expression in a similar manner to that observed by RU-486 and the non-steroidal 
PRA, WAY-255348 (de Giorgio-Miller et al., 2008; Fensome et al., 2008). These data are 
consistent with other non-steroidal PRAs that have been assessed, such as WAY-255348 
(Fensome et al., 2008). More recently, PF-02413873 a more potent PRA than PF-02367982 
(Table 1) has been shown to reduce endometrial cell proliferation and thickness in intact 
macaques dosed for 10 days from the start of menstruation (Howe et al., 2011). In this study, 
however, AR expression was not appreciably altered with PF-02413873 treatment compared 
with RU-486. While this may be, in part, due to the timepoint for the comparison and 
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assessment, PF-02413873 also appears to have a different pharmacological profile from RU-
486 and other steroidal PRAs.  
While these interesting observations are important in the context of normal endometrial 
physiology, few studies have been undertaken in macaques with endometriosis to build 
translational understanding to disease. Menstruating primates, such as the baboon and the 
macaque, develop spontaneous endometriosis and ectopic lesions that are histologically 
identical to the human disease (D'Hooghe et al., 2009). For many researchers, the proximity 
of this model to the human condition has made this the model of choice for the assessment 
of interventional agents the endometriosis. Spontaneous disease is acquired with a similar 
time course as experienced by the human female, developing slowly over a period of years 
and is not easily diagnosed without laparoscopy. Consequently, researchers have used 
intraperitoneal inoculation of autologous menstrual or endometrial tissue to develop an 
experimental model of endometriosis that is similar to that observed in women. 
The only study evaluating the effect of a steroidal PRA, RU-486, in a non-human primate 
model of endometriosis was reported by Grow et al (1996). This study was undertaken in a 
surgical induction model of endometriosis and disease allowed to develop prior to dosing. 
A baseline measure of burden (peritoneal lesion area) was undertaken and then macaques 
were treated with either RU-486, leuprolide or vehicle for one year. Both RU-486 and 
leuprolide induced an anovulatory amenorrhoea and reduced peritoneal disease levels to a 
similar levels, >75%, compared with the vehicle control group. The authors additionally 
evaluated the effect of RU-486 and leuprolide on bone mineral density as revealed by dual 
x-ray absorptiometry. Consistent with the post-menopausal levels of E2 achieved, leuprolide 
induced a 0.035 g/cm2 reduction in bone mass compared with +0.1 g/cm2 for vehicle control 
and +0.25 g/cm2 for the RU-486 treated animals. These data support earlier observations 
that steroidal PRAs are able to suppress endometrial cell growth whilst maintaining bone-
sparing mid-follicular levels of E2 (Heikinheimo et al., 1995). 
6. Clinical evaluation in healthy women and women with endometriosis  
RU-486 was originally developed for emergency contraception, however early observations 
with lower doses than those used clinically, indicated that when given acutely during the 
luteal phase, RU-486 would facilitate the onset of menstruation by the upregulation of 
endometrial prostaglandins and given chronically, RU-486 would delay menses 
(Hapangama et al., 2002; Shoupe et al., 1987). The effects of RU-486 on the ovarian cycle and 
endometrium appear to be dose dependent, that is low doses interfere with estrogen 
function and disrupt endometrial growth (Croxatto et al., 1993; Narvekar et al., 2004), but 
higher doses additionally suppress follicular development by impairing gonadotrophin 
secretion (Gemzell-Danielsson et al., 1996; Liu et al., 1987; Spitz et al., 1993; 1994). These 
observations strike a resounding chord with those data acceded in the macaque described 
earlier. The potential value of PRAs as alternative contraceptives to current combined or 
progestin-only pills have been long recognised and evaluated in a number of different 
dosing and delivery strategies (Baird et al., 2003; Brown et al., 2002; Chabbert-Buffet et al., 
2007; Heikinheimo et al., 2007; Lakha et al., 2007; Nayak et al., 2007). Whilst no pregnancies 
were reported after 200 months in women who received 2-5 mg RU-486 daily (Brown et al., 
2002), lower doses appeared to be less effective (Croxatto et al., 1998). Similar observations 
on the suppression of ovulation and the normal menstrual cycle have also been made with 
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other PR-As such as a onapristone, J-876 as well as CDB-2914 (Chabbert-Buffet et al., 2007; 
Chwalisz et al., 2005a; Katkam et al., 1995; Stratton et al., 2000). The utility of PRAs as a new 
class of oral contraceptives has still not been fully exploited and this feature alone is 
anticipated to have potential benefit in endometriosis patients by reducing cyclical 
menstrual pain. 
Intrauterine delivery (IUD) of progestogens (levonorgestrel/Mirena) is an effective way of 
administering durable contraceptive exposures of drug and to bypass systemic side effects. 
IUD studies with PRAs in the macaque have also been followed up with a single human 
study. The study compared levonorgestrel with an IUD releasing ZK-230211. The dose of 
ZK-230211 was selected based on an equivalent IUD dose of ZK-230211 that suppressed 
ovulation and menstruation in the macaque (Heikinheimo et al., 2007). In contrast to the 
data acceded in the macaque, however, the ZK-230211 IUD did not appreciably alter 
bleeding patterns suggesting that either the local drug exposure was insufficient or that 
there are translational differences between the macaque and human. 
Increasingly, however, the endometrial effects of PRAs have been subject to concern due 
observed histological changes in the endometrium with chronic exposure. In the past, 
endometrial hyperplasia has been reported as a safety concern with chronic use of RU-486 
(Newfield et al., 2001). Recent, detailed histological analyses of endometrial biopsies from 
patients exposed to steroidal PRA for more than 3 months have indicated that these agents 
produce a slightly thickened endometrium with cystically dilated endometrial glands (Ioffe 
et al., 2009; Mutter et al., 2008; Williams et al., 2007). The appearance of glandular 
epithelium appears to change with dose and exposure duration, from inactive/non-mitotic 
to non-physiologic combinations of features usually seen separately in normal proliferative 
and secretory endometrium. These alterations do not appear to be limited to the glands 
only, as thick-walled vessels most commonly seen in endometrial polyps, become more 
widely distributed throughout the endometrium. Whether these effects on the endometrium 
are mediated by the unopposed effects of persistent follicular phase levels of estradiol, the 
pharmacological class or some non-specific effect of PRAs on the endometrium is not clear, 
but this appears to be a common feature of all steroidal PRAs assessed so far. Individuals on 
prolonged exposure to asoprisnil/J-867 were at a higher risk of developing endometrial 
changes sufficient to raise concern with regulatory authorities indicates that more research is 
needed to understand the phenomenon of PRA associated endometrial changes and 
whether this might be in part mitigated by an alternative dosing regimen from continuous 
dosing (Baird et al., 2003). 
The first evidence that PRAs such as RU-486 would have a potential benefit in women 
with endometriosis was published by Kettel and co-workers (1991; 1994; 1996; 1998). The 
incentive for these early investigational studies was the clinical observation that RU-486 
could block follicular maturation and ovulation when given early in the menstrual cycle, 
disrupt endometrial integrity when administered in the luteal phase and induce an 
anovulatory amenorrhoea when administered continuously. However, even earlier 
studies than those conducted with RU-486, indicated the potential utility of treating 
women with endometriosis with an anti-progestin (Coutinho, 1982). In this small open-
label study, 20 patients with endometriosis were subjected to 6 months of continuous 
treatment with gestrinone (5 mg/twice weekly), a reportedly mixed antagonist with anti-
progestogenic activity. All subjects became amenorrhoeic and had reportedly dramatic 
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improvements in dyspareunia symptoms and fertility outcomes. Whilst no visualisation 
of the change in the disease burden was made in this study, this assessment was followed 
up by others (Cornillie et al., 1986) and incorporated as part of the validation work 
performed by Kettel and co-workers with RU-486. In these studies, doses of RU-486 were 
carefully selected to avoid the known anti-glucocorticoid effects. Treatment of women 
with endometriosis with a daily dose of 5-100 mg for 3-6 months resulted in durable 
inhibition of the normal menstrual cycle (although not optimal for the 5 mg dose) and a 
suppression in ovarian hormone levels consistent with a block on folliculogenesis. 
Endometriosis-associated pain scores and American Fertility Scores determined by 
laparoscopic examination also decreased from baseline (Kettel et al., 1994; 1996; 1998; 
Murphy et al., 1995). These preliminary studies were not able to rule out the possibility 
that the visible changes in disease burden were secondary to the absence of ovarian 
hormone cyclicity; indeed this is still not known. From a safety perspective, there was no 
suppression of cortisol levels, indicative of anti-glucocorticoid effects. Serum estradiol 
concentrations were also maintained at a mid-follicular level which preserved femur and 
lumbar spinal bone mineral density (Kettel et al., 1996). These bone safety data are 
consistent with those reported in the cynomolgus macaque and contrast clinical 
observations of GnRH receptor agonists (Grow et al., 1996). 
Asoprisnil has also been compared with placebo for treatment of pain in laparoscopically 
diagnosed endometriosis in a randomized, controlled trial. Whilst the results of this study 
were reported as an abstract only, a significant decrease in daily pain scores with all doses of 
asoprisnil (5, 10 or 25 mg) compared with placebo was noted (Chwalisz et al., 2005b). 
Intriguing as these data are, there has been a compelling lack of replication studies from 
double blinded, randomised and controlled trials in women with endometriosis, using 
empirical and objective outcome measures approved by regulatory bodies. This lack of 
evidence may be in part due to the level of investment needed for such an old drug as RU-
486, or concerns over the safety of continuously administered RU-486 or PRAs like it. CDB-
4124 is currently in development for the treatment of endometriosis and uterine fibroids and 
data are anticipated on its clinical efficacy/safety profile. 
In contrast to the relatively large wealth or reported data with steroidal PRAs, there is only a 
single study evaluating the effects of a non-steroidal PRA, PF-02413873, in healthy female 
subjects (Howe et al., 2011). When orally dosed to healthy female volunteers, daily from the 
first day of the menstrual cycle, PF-02413873 blocked the mid-cycle LH surge and 
endometrial growth (Figure 3). 
Whilst PF-02413873 development for endometriosis was curtailed due to a high incidence of 
idiosyncratic maculopapular rash, PF-02413873 proves the principle that a non-steroidal 
PRA can similarly block the effects of follicular hormones on endometrial growth as 
steroidal PRAs. Further data are needed to determine whether the histological changes 
encountered by the class of steroidal PRAs endometrial are similarly manifested by the non-
steroidal PRA class. 
Given the anti-proliferative effects observed in vitro and in vivo for PRAs (Freeburg et al., 
2009b; Goyeneche et al., 2007; Ohara et al., 2007; Poole et al., 2006; Tieszen et al., 2011), the 
broader utility of this class in treating other benign and malignant growth conditions has 
not gone unnoticed (Chwalisz et al., 2007; Robertson et al., 1999; Rocereto et al., 2000; 
Wilkens et al., 2008). In the closely related condition of uterine fibroids, small studies have 
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demonstrated a reduction in myoma volume and uterine bleeding with asoprisnil and RU-
486 (Chabbert-Buffet et al., 2005; DeManno et al., 2003; Fiscella et al., 2006). Larger studies 
have been completed for asoprisnil. In one randomized, controlled trial, 129 women with at 
least 1 fibroid greater than 3 cm in diameter or a uterine volume twice the normal (>200 cm3) 
were treated for up to 3 months with asoprisnil (5, 10, or 25 mg) or placebo (Chwalisz et al., 
2007). Significant reduction in uterine fibroid volume was noted by week 4 and persisted 
through the end of the study in a dose-dependent fashion. 
a                                                               b
 
Fig. 3. Effect of escalating multiple dose of PF-02413873 on endometrial thickness (mm) (a) 
and the mid cycle LH surge (mIU/mL) (b) in healthy women compared with placebo (Howe 
et al., 2011) 
7. Conclusion 
There are compelling pre-clinical and clinical evidence to suggest that as well as directly 
antagonising the effect of progesterone, PRAs also functionally antagonise the effects of 
estrogen on the endometrium. This coupled with the suppression of ovarian folliculogenesis 
induces anovulatory amenorrhoea. Evaluation of the PR axis in animal models of 
endometriosis has suggested that PRAs can suppress the growth of ectopic endometriotic 
lesions. The mechanism driving this effect is still not clear, but it sufficient to maintain 
ovarian activity and estradiol levels adequately to protect bone as well as other potential 
post-menopausal symptoms more commonly encountered with ovarian suppression. In 
women with endometriosis, the data available from small clinical evaluations, strongly 
suggest that PRA treatment reduces disease symptoms, whilst maintaining normal levels of 
bone mineral density. Further clinical evaluation in larger randomised, placebo controlled 
and blinded studies are warranted, both to underscore the clinical benefit as well as 
understand the safety of the mechanism compared with existing standard of care therapy 
(endometrial, cardiovascular and bone safety, in particular). The medicinal chemistry 
challenge in designing potent, selective and safe PRAs is not inconsiderable, especially 
given the large number of examples whose clinical development have been curtailed (e.g. 
onapristone, PF-02413873, asoprisnil). However, the clinical evidence observed so far 
provides strong confidence that the class could have utility as a chronic treatment for 
endometriosis as well as a range of other gynaecological indications and malignant 
conditions. 
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